Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK3486 vs Propofol for Sedation in ICU Patients
NCT04669821Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cipepofol in sedation (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Mean duration of qualified sedation at 96 hours. Started Mar 2021; status: completed.
02
Drugs
cipepofol
03
Conditions
sedation
Beyond the preview
Go deeper on NCT04669821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669821.